In further agreement, treatment of melanoma-bearing mice with kineret, a recombinant human IL-1 receptor antagonist, confirmed IL-1β as a critical factor controlling bcl-2 regulation of immune cells, since it significantly reduced tumor growth and expression of the M2 marker CD206 by TAM, while in contrast, it enhanced the IFNγ production by both CD4 and CD8 T cells as well as the number of tumor-infiltrating effector memory T cells. This evidence concerns the gene BCL2 and melanoma.